Following its prominence during the COVID-19 pandemic, the biotech industry has resumed its regular pace, with the focus on combating the virus diminishing. However, the industry looks well-positioned for long-term growth.
Therefore, it could be wise to buy fundamentally strong biotech stocks, Entrada Therapeutics (TRDA) and ProQR Therapeutics N.V. (PRQR). On the other hand, 4D Molecular Therapeutics, Inc.’s (FDMT) poor fundamentals and growth prospects make it best avoided now.
